Tumor Myeloid Microenvironment Directed Therapeutics Summit 2021

Memo

With the explosive excitement and clinical proof of concept utilizing CD47 approaches, 2020 is the year for macrophage development, as we witness greater interest and investment in new work on novel macrophage targets outside of CD47. Tumor Myeloid Microenvironment Directed Therapeutics Summit is focused on optimizing the potential of immunotherapy, through direct modulation of tumor-resident myeloid populations to retune the microenvironment for improved response rates to therapy. Additionally, we’ll take a close look at how therapeutics can be designed to directly stimulate these populations to kill cancer Join us online in March as the trailblazers of myeloid directed therapeutic development, from the likes of Carisma Therapeutics, Pfizer, Merck and Co., and Verseau Therapeutics come together to advance the fundamental understanding of macrophage biology, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy. On Tuesday March 16, 2021 at 9:00 am (ends Thursday March 18, 2021 at 5:00 pm) Prices: Conference Only - Pharma and Biotech Pricing: USD 1799.00,Conference + 1 Workshop - Pharma and Biotech Pricing: USD 2098.00,Conference + 2 Workshops - Pharma and Biotech Pricing: USD 2397.00,Conference Only - Academic and Not-for-Profit Pricing: USD 1499.00,Conference + 1 Workshop - Academic and Not-for-Profit Pricing: USD 1748.00,Conference + 2 Workshops - Academic and Not-for-Profit Pricing: USD 1997.00,Conference Only - Standard Pricing: USD 2199.00,Conference + 1 Workshop - Standard Pricing: USD 2598.00,Conference + 2 Workshops - Standard Pricing: USD 2997.00 URLs: Tickets: https://go.evvnt.com/701752-0?pid=5569 Brochure: https://go.evvnt.com/701752-3?pid=5569 Speakers: Peter Ellmark, Alligator Bioscience AB, Victoria Smith, Amphivena Therapeutics Inc., Kaiming Ye, Binghamton University, Michael Klichinsky, Carisma Therapeutics, Peter Lee, City of Hope Comprehensive Cancer Center, Alex Swarbrick, Garvan Institute of Medical Research, Naval Daver, MD Anderson Cancer Center, Caroline Bonnans, Immune-Onc Therapeutics, Jessica Haverkamp, Merck and Co, Daniel Getts, Myeloid Therapeutics, Michele Gerber, Myeloid Therapeutics, Pushpa Jayaraman, Novartis, Barbara Platzer, Novartis Institutes for BioMedical Research, Lisa Coussens, Oregon Health and Science University, Victor Levitsky, Targovax, Gael Roue, Josep Carreras Leukaemia Research Institute, Tatiana Novobrantseva, Verseau Therapeutics, Phuong Anh (Ani) Nguyen, Verseau Therapeutics, Ryan Phennicie, Generate Biomedicines, Katherine Seid, SQZ Biotech, Jo Van Ginderachter, Vrije University Brussels, Yifan Zhan, Huabo Biopharm, Gloria Lin, Trillium Therapeutics Inc.